DGAP-News: HAEMATO AG

HAEMATO AG Corporate News:
2017: According to the preliminary IFRS results, Haemato AG increased its sales by 5.2% to EUR 289.9 million.

In 2017, HAEMATO AG, Berlin (ISIN: DE0006190705), achieved an IFRS group turnover of EUR289,9m (previous year: EUR275.6m), an operating result (EBIT) of EUR9.4 (previous year: EUR13.4m), and an annual net profit of EUR6.98m (previous year: EUR10.7m). A capital increase of EUR 7.4 million improved the equity ratio from 54% (2016) to 58% in 2017.

After the exceptional year 2016, the results stabilized at a high level.

After a cautious start into 2017, the HAEMATO Group made significant gains in the second half of the year and exceeded its expectations of EBIT (EUR 8.28 million), EBITDA (EUR 10.1 million) and net income.

As a supplier of specialty pharmaceuticals, the HAEMATO Group is growing faster than the market. The specialization in medications for the treatment of chronic diseases means that demographic trends will continue to lead to above-average growth in the future.

The addition of the product range to high-margin medical products is being consistently further developed. In December 2017, the first care products based on Hyaluronan were delivered.

The earnings situation allows the Executive Board to propose an unchanged dividend of 30 cents per share to the Supervisory Board.

About HAEMATO:

HAEMATO AG, which was founded in 1993, is a pharmaceutical company. The focus of the operational activities is on the growth markets of patent-free and patent-protected pharma-ceuticals. Focal points are therapies of cancer, HIV, and other chronic diseases.

HAEMATO AG is listed in the Basic Board (Open Market) of the Frankfurt Stock Exchange. Key figures for the HAEMATO AG share:
Subscribed capital: EUR20,778,898
Listed class of share: Bearer shares
ISIN: DE000619070
WKN: 619070
Ticker symbol: HAE